Business Context and Reporting Period
This Form 6-K filing by Evaxion Biotech A/S covers corporate actions taken in January 2025. The report details the exercise of pre-funded warrants, subsequent amendments to the Articles of Association, and resolutions passed at an Extraordinary General Meeting held on January 17, 2025.
Key Financial Metrics and Capital Structure
- Share Capital Increase: The Company registered an aggregate nominal increase of DKK 8,510,000 in ordinary shares effective January 7 and January 15, 2025, following the exercise of pre-funded warrants at $1.4537 per ADS.
- Total Share Capital (Pre-Reduction): Following the warrant exercises, the nominal share capital stood at DKK 78,640,556.
- Share Capital Reduction: Shareholders approved a reduction of nominal DKK 58,980,417 to cover losses.
- Post-Reduction Share Capital: The nominal share capital was reduced to DKK 19,660,139.
- Nominal Share Value: The nominal value per share was reduced from DKK 1.00 to DKK 0.25.
- Outstanding Shares: The total number of shares remains 78,640,556 following the reduction.
- Meeting Participation: 15,308,584 ordinary shares (20.1% of outstanding shares) were voted at the Extraordinary General Meeting.
Note: The filing does not provide specific values for revenue, profit, cash flow, operating margins, debt levels, or liquidity ratios.
Material Changes Versus Prior Period
- Capital Structure Adjustment: Between the notice date (December 20, 2024) and the meeting date, the share capital increased due to warrant exercises. Consequently, the Board adjusted the proposed capital reduction to maintain the intended proportional reduction (one-quarter of the capital) relative to the new total.
- Warrant Status: There are no remaining pre-funded warrants issued under Appendix 7 of the Articles of Association following the January 2025 exercises.
- Corporate Governance: Lars Lüthjohan was elected as the chairman of the Extraordinary General Meeting.
Outlook, Risks, and Management Commentary
- Loss Coverage: The primary driver for the capital reduction is to cover accumulated losses. The reduction was structured to ensure all shareholders are treated equally despite the interim capital increase.
- Warrant Adjustments: The Board will adjust issued warrants pursuant to applicable clauses to reflect the changes in share capital and nominal value.
- Future Authorizations: No amendments were made to existing authorizations for the Board to issue shares, convertible bonds, or warrants.
- Regulatory Compliance: The Company has filed amended Articles of Association with the Danish Business Authority to reflect these changes.
Key Facts for Investor Verification
- Verify the final registration of the share capital reduction (DKK 19,660,139) and the new nominal share value (DKK 0.25) with the Danish Business Authority.
- Confirm the specific adjustment terms applied to existing outstanding warrants to ensure proper conversion ratios post-reduction.
- Review the Company's latest approved annual report and auditor declaration referenced in the meeting materials to understand the magnitude of the losses being covered.
- Monitor future filings for any impact on the Company's liquidity position following the capital reduction and warrant exercises.